Ipilimumab in Renal Cell Carcinoma
|Drug class||Target||Agent||Diseases||Line of Therapy||Status||Source|
|CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody||CTLA-4||ipilimumab (Yervoy)||renal cell carcinoma||metastatic||FDA Approved||Motzer et al. 2018|
In a phase III trial, over a thousand renal cell carcinoma patients were randomized to receive nivolumab plus ipilimumab followed by nivolumab or sunitinib. In the intermediate- and poor-risk patients, overall survival was significantly higher with the combination therapy of nivolumab plus ipilimumab (Motzer et al. 2018). Ipilimumab was approved in combination with nivolumab for the treatment of patients with intermediate and poor risk renal cell carcinoma in 2018 (FDA 2018).
|Reference||Study Type / Phase||Line of Treatment||Treatment Agent||Patient cohort||# Patients in Study||Response Rate||PFS (months)||OS (months)|
|Motzer et al. 2018||Phase III||1st line||nivolumab + ipilimumab||Intermediate- and Poor-Risk Patients||425||42%||11.6||not reached|
|sunitinib||Intermediate- and Poor-Risk Patients||422||27%||8.4||26|
Last Updated: May 24, 2018